Navigation Links
Second Ohio State cancer drug begins clinical trials testing
Date:6/18/2010

COLUMBUS, Ohio For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

This week, adult patients began receiving doses of the potentially groundbreaking drug, which is designed to treat relapsed or treatment-resistant multiple myeloma, chronic lymphocytic leukemia or lymphoma, said Dr. John Byrd, associate director of clinical translational research at OSUCCC-James and a leukemia specialist who initiated the drug's development with Ching-Shih Chen, an Ohio State cancer researcher and medicinal chemist.

The new phase I/IIa clinical trial will assess the safety and initial evidence of activity of the oral drug AR-42, which belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process. Ohio State is the only site worldwide accepting patients to the clinical trial, said Byrd.

"Early tests in cancer cell models showed that AR-42 is 10,000 fold more potent than the starting/parent agent," said Chen, a professor of pharmacy, urology and internal medicine who holds the Lucius A. Wing chair of cancer research.

In 2003, Byrd asked Chen to try to improve the potency of a short-chain fatty acid known to have a weak inhibitory effect against cancer growth. Chen worked with cancer center and pharmacy colleagues at Ohio State to develop the drug originally called OSU-HDAC42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC).

The agent has been licensed to the biopharmaceutical company Arno Therapeutics, Inc., for clinical development.

"It is exciting to see this very potent broad class I/II HDAC inhibitor enter the clinic for treatment of blood cancers and we look forward to generating meaningful clinical results from in this Phase I/IIa study," said Byrd. "We are incredibly grateful to organizations that have supported this effort to bring this drug forward to our blood cancer patients.

Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and chief executive officer of the James Cancer Hospital and Solove Research Institute, praised the collaborative efforts of Ohio State researchers who worked more than 7 years to develop this drug.

"We are encouraged by its preclinical activity, and feel that this molecule could have meaningful clinical implications in a variety of cancers," said Caligiuri.

Dr. Michael Grever, chairman of the department of internal medicine at Ohio State and co-leader of the Experimental Therapeutics program at OSUCCC-James, was instrumental in moving this experimental agent from bench to bedside.


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. American Doctor Misses World Cycling Record by 4 minutes, 57 Seconds
2. Smoke-free air laws effective at protecting children from secondhand smoke
3. Second-line CML drugs evoke faster, better front-line remissions
4. Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
5. Career Training College, Pima Medical Institute, Offering Second Bachelor's Degree Program in Respiratory Therapy
6. BioConference Live Announces Speakers and Sponsors for Second Edition of Premier Online Conference for Life Science Community
7. Smoking Ups Risk of Second Breast Cancer
8. Cambridge Healthtech Institute to Host Its Second Annual Collaborative Innovation in Biomedicine Conference
9. Second volume of groundbreaking Emerging Model Organisms series is released
10. Second AGA Foundation/Bernard Lee Schwartz Foundation Research Scholar Award presented
11. Secondhand Smoke Boosts Sinusitis Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 28, 2016 , ... "Color Grading media can be time consuming but with ... media," said Christina Austin - CEO of Pixel Film Studios. , With the ... stylish color grades to their footage. A LUT is a Lookup Table that contains ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Two director-level ... as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes ... workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute ... for a sustainable product to aid in the rehabilitation process has steadily increased. Ekso ... of individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
Breaking Medicine Technology: